In 2010, the therapeutic cancer vaccine market witnessed several key
milestones. Dendreon' s Provenge (sipuleucel-T) became the first product to
reach the market; gaining long-awaited FDA approval for metastatic
hormone-refractory prostate cancer. The Cancer Research Institute (CRI) and
the Cancer Immunotherapy Consortium (CIC) also proposed much needed criteria
to standardize vaccine clinical trials.
Although the major milestones attained in the clinical development of
therapeutic cancer vaccines has brought hope and guidance for investors, the
market is in its commercial infancy. According to Arrowhead' s new publication:
The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future
Market Impact, numerous challenges must be overcome to create optimal
vaccines on an economical scale. Stakeholders can learn from Provenge' s
developmental pathway to maximize success in this potentially lucrative market.
With over 1.3 million people having been diagnosed with colorectal cancer,
breast cancer, lung cancer, prostate cancer, pancreatic cancer or melanoma
across the seven major markets in 2010, coupled with unsatisfactory survival
rates; vaccines could hold the ability to transform the management of cancer.
This in-depth report provides:
- An identification and analysis of the major challenges within therapeutic
cancer vaccine R&D including clinical trial standardization recommendations ,
designing optimal vaccines and the lessons learnt from Provenge' s development
- Clinical and commercial analysis of key Phase III oncology vaccine
- An overview and analysis of the current markets for the treatment of
- Insight from key opinion leaders (KOLs) on the future applicability of
therapeutic vaccines for the treatment of cancer
- Sales growth rates to 2020 for key products in development
Traditional cancer clinical trial endpoints are not always applicable in the
assessment of cancer vaccines. Lengthy trials allowing full data maturation of
measuring immune response is limiting market entry. R&D must establish an
effective and consistent way to assess vaccines.
Arrowhead has identified almost 400 clinical trials investigating therapeutic
oncology vaccines. Whole-cell vaccines are the most popular design in
late-stage development. Arrowhead anticipates a wave of products to reach the
market over the coming decade.
The market is set to become highly competitive, especially within the lung
cancer and melanoma sectors. By 2020 the market could be worth $8 billion. Top
revenue earning candidates include GSK' s MAGE-ASCI-A3, Merck/Oncothyreon' s
Stimuvax (BLP25), NovaRX' s Lucanix and Lorus Therapeutics/Zor Pharma' s
Key questions answered by this report
- How can therapeutic cancer vaccine clinical trials be optimized to aid
regulatory approval and commercial success?
- What lessons can stakeholders learn from Provenge' s developmental and
- What is the optimal design of a therapeutic cancer vaccine?
- What candidates are in the current therapeutic cancer vaccine pipeline?
- What are the key pipeline therapeutic cancer vaccine candidates in
- What are the clinical and commercial attributes of key late-stage
therapeutic cancer vaccine candidates?
- Which biopharmaceutical companies are involved in the arena?
- What revenues will therapeutic cancer vaccine products generate over the
next coming decade?
- Which cancer types will realize the greatest benefits from vaccines?
- What major challenges face the arena over the coming years; and how can
these be overcome?
- What advice do leading expert immunology/oncology vaccine developers give
to stakeholders in the arena?
- What are the greatest commercial opportunities within the future
therapeutic cancer vaccine market?
Reasons to buy this report
- Identify key therapeutic cancer vaccine candidates in late-phase
development based on sales forecasts to 2020 to maximize your products
- Assess opportunities and risks influencing R&D in therapeutic cancer
- Gain an impartial perspective of strategies that can be used to enhance
new product performance in the therapeutic cancer vaccine market
- Better understand how cancer vaccines will fit into future therapeutic
regimens for cancer